LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Wedbush Is Increasing Apogee Therapeutics, Inc. (APGE) Q1 25 Estimate To -0.63 From -0.75 5/13/2024 4:53:51 PM
  • Wedbush Is Increasing Apogee Therapeutics, Inc. (APGE) FY24 Estimate To -2.43 From -2.89 5/13/2024 4:53:40 PM
  • Wedbush Is Increasing Apogee Therapeutics, Inc. (APGE) Q4 24 Estimate To -0.61 From -0.74 5/13/2024 4:53:29 PM
  • Wedbush Is Raising Apogee Therapeutics, Inc. (APGE) Q3 24 Estimate To -0.60 From -0.73 5/13/2024 4:53:03 PM
  • Wedbush Is Raising Apogee Therapeutics, Inc. (APGE) Q2 24 Estimate To -0.59 From -0.71 5/13/2024 4:52:49 PM
  • Wedbush Reiterates Apogee Therapeutics, Inc. (APGE) At Outperform With $87 Price Target 5/13/2024 4:52:25 PM
  • Apogee Therapeutics Q1 Net Loss $32.09 Mln Vs. Net Loss $12.54 Mln Last Year 5/13/2024 7:37:12 AM
  • Wedbush Reiterates Apogee Therapeutics, Inc. (APGE) At Outperform With $87 Price Target 3/25/2024 11:08:47 PM
  • Apogee Therapeutics Doses First Participants In Phase 1 Trial Of APG808 For COPD And Other Inflammatory Diseases 3/25/2024 7:21:47 AM
  • Wedbush Is Lowering Apogee Therapeutics, Inc. (APGE) FY24 Estimate To -2.89 From -2.17 3/5/2024 10:59:01 AM
  • Wedbush Is Lowering Apogee Therapeutics, Inc. (APGE) Q4 24 Estimate To -0.74 From -0.62 3/5/2024 10:58:48 AM
  • Wedbush Is Lowering Apogee Therapeutics, Inc. (APGE) Q3 24 Estimate To -0.73 From -0.57 3/5/2024 10:58:35 AM
  • Wedbush Is Cutting Apogee Therapeutics, Inc. (APGE) Q2 24 Estimate To -0.71 From -0.51 3/5/2024 10:58:22 AM
  • Wedbush Is Cutting Apogee Therapeutics, Inc. (APGE) Q1 24 Estimate To -0.70 From -0.47 3/5/2024 10:58:07 AM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap